Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue

Richard J. Robbins; Robert H. Hill; Weiping Wang; Homer H. Macapinlac; Steven M. Larson

doi:10.1089/thy.2000.10.177

Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue

Richard J. Robbins, Robert H. Hill, Weiping Wang, Homer H. Macapinlac, Steven M. Larson

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Two patients with widely metastatic papillary thyroid cancer demonstrated progressive growth of diffuse pulmonary lesions. One patient had no apparent response to high doses of ¹³¹I and the other hand no ¹³¹I uptake. ¹¹¹In-pentetreotide scans revealed that many of the metastatic lesions expressed somatostatin receptors. The baseline metabolic activity and three-dimensional volume of the lesions were determined by ¹⁸F-fluoro- deoxyglucose positron emission tomography (FDG-PET). After 3 or 4 months of octreotide (Sandostatin LAR Depot®; Novartis Pharmaceutical, East Hanover, NJ) therapy, repeat FDG-PET scans revealed reductions in tumor volume and decreases in the standard uptake values of FDG. We conclude that octreotide therapy can change the biological activity of metastatic thyroid cancer lesions that exhibit somatostatin receptors.

Original language	English (US)
Pages (from-to)	177-183
Number of pages	7
Journal	Thyroid
Volume	10
Issue number	2
DOIs	https://doi.org/10.1089/thy.2000.10.177
State	Published - Feb 2000
Externally published	Yes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1089/thy.2000.10.177

Cite this

@article{1002f158706e436b836102670268b73d,

title = "Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue",

abstract = "Two patients with widely metastatic papillary thyroid cancer demonstrated progressive growth of diffuse pulmonary lesions. One patient had no apparent response to high doses of 131I and the other hand no 131I uptake. 111In-pentetreotide scans revealed that many of the metastatic lesions expressed somatostatin receptors. The baseline metabolic activity and three-dimensional volume of the lesions were determined by 18F-fluoro- deoxyglucose positron emission tomography (FDG-PET). After 3 or 4 months of octreotide (Sandostatin LAR Depot{\textregistered}; Novartis Pharmaceutical, East Hanover, NJ) therapy, repeat FDG-PET scans revealed reductions in tumor volume and decreases in the standard uptake values of FDG. We conclude that octreotide therapy can change the biological activity of metastatic thyroid cancer lesions that exhibit somatostatin receptors.",

author = "Robbins, {Richard J.} and Hill, {Robert H.} and Weiping Wang and Macapinlac, {Homer H.} and Larson, {Steven M.}",

year = "2000",

month = feb,

doi = "10.1089/thy.2000.10.177",

language = "English (US)",

volume = "10",

pages = "177--183",

journal = "Thyroid",

issn = "1050-7256",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue

AU - Robbins, Richard J.

AU - Hill, Robert H.

AU - Wang, Weiping

AU - Macapinlac, Homer H.

AU - Larson, Steven M.

PY - 2000/2

Y1 - 2000/2

N2 - Two patients with widely metastatic papillary thyroid cancer demonstrated progressive growth of diffuse pulmonary lesions. One patient had no apparent response to high doses of 131I and the other hand no 131I uptake. 111In-pentetreotide scans revealed that many of the metastatic lesions expressed somatostatin receptors. The baseline metabolic activity and three-dimensional volume of the lesions were determined by 18F-fluoro- deoxyglucose positron emission tomography (FDG-PET). After 3 or 4 months of octreotide (Sandostatin LAR Depot®; Novartis Pharmaceutical, East Hanover, NJ) therapy, repeat FDG-PET scans revealed reductions in tumor volume and decreases in the standard uptake values of FDG. We conclude that octreotide therapy can change the biological activity of metastatic thyroid cancer lesions that exhibit somatostatin receptors.

AB - Two patients with widely metastatic papillary thyroid cancer demonstrated progressive growth of diffuse pulmonary lesions. One patient had no apparent response to high doses of 131I and the other hand no 131I uptake. 111In-pentetreotide scans revealed that many of the metastatic lesions expressed somatostatin receptors. The baseline metabolic activity and three-dimensional volume of the lesions were determined by 18F-fluoro- deoxyglucose positron emission tomography (FDG-PET). After 3 or 4 months of octreotide (Sandostatin LAR Depot®; Novartis Pharmaceutical, East Hanover, NJ) therapy, repeat FDG-PET scans revealed reductions in tumor volume and decreases in the standard uptake values of FDG. We conclude that octreotide therapy can change the biological activity of metastatic thyroid cancer lesions that exhibit somatostatin receptors.

UR - http://www.scopus.com/inward/record.url?scp=0033997649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033997649&partnerID=8YFLogxK

U2 - 10.1089/thy.2000.10.177

DO - 10.1089/thy.2000.10.177

M3 - Article

C2 - 10718556

AN - SCOPUS:0033997649

SN - 1050-7256

VL - 10

SP - 177

EP - 183

JO - Thyroid

JF - Thyroid

IS - 2

ER -

Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this